BioCentury | Apr 11, 2011
Finance

Playing tax arbitrage

Cephalon Inc. rejected Valeant Pharmaceuticals International Inc. 's hostile bid last week as too low, but the advantages Valeant's tax structure provides make it hard to see how Cephalon can compete for the affections of...
BioCentury | Feb 14, 2011
Finance

Next phase for Phase4

Phase4 Ventures expects to focus more on European investment following its spinout from Nomura. The firm will be raising its first independent fund sometime over the next 12 months. The new firm expects to invest...
BioCentury | Jan 10, 2011
Strategy

A Remembrance: Force of Nature

From the moment you met him, you knew you were dealing with a Force of Nature. A rare combination of determination, imagination and genuine warmth, Frank Baldino was a formidable presence in the life science...
BC Week In Review | Apr 19, 2010
Company News

Cephalon, Mepha deal

Cephalon completed its previously announced acquisition of generics company Mepha for CHF662.4 million ($623.4 million) in cash. Mepha will become a wholly owned subsidiary of Cephalon (see BioCentury, Feb. 8). Cephalon Inc. (NASDAQ:CEPH), Frazer, Pa....
BC Extra | Feb 12, 2010
Financial News

Cephalon beats Street

Cephalon Inc. (NASDAQ:CEPH) report 4Q09 diluted adjusted EPS of $1.66, beating by $0.08 the Street's estimate of $1.58 and up 14% from $1.46 in 4Q08. Fourth quarter revenues were $575.1 million, above the Street's estimate...
BC Week In Review | Feb 8, 2010
Company News

Cephalon, Mepha AG deal

Cephalon announced on Feb. 1 that it will acquire generics company Mepha for CHF622.5 million ($587.9 million) in cash. Cephalon said the deal will expand its generics and branded generics business and double the size...
BioCentury | Feb 8, 2010
Strategy

Footprint for growth

Investors often worry that when companies add low-margin products to a high-margin portfolio, earnings will suffer. Cephalon Inc. Chairman and CEO Frank Baldino says the company's proposed acquisition of generics company Mepha AG should allow...
BioCentury | Feb 8, 2010
Finance

Regulatory milestones

Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) gained $2.88 (10%) to $31.04 last week after FDA approved a BLA for Xiaflex collagenase clostridium histolyticum to treat Dupuytren's contracture, a condition that affects the joints in the hand. Auxilium...
BC Extra | Feb 2, 2010
Top Story

Cephalon to acquire Mepha

Cephalon Inc. (NASDAQ:CEPH) will acquire generics company Mepha AG (Basel, Switzerland) for CHF622.5 million ($587.9 million) in cash. Cephalon said the deal will expand its range of products and double the size of its international...
BC Week In Review | Sep 25, 2000
Company News

Cephalon sales and marketing update

CEPH launched in Switzerland its Modasomil modafinil oral alpha adrenergic stimulant to treat narcolepsy. CEPH licensed Swiss rights to the compound from Mepha Pharma AG (Basel, Switzerland). CEPH markets modafinil under the name Provigil in...
Items per page:
1 - 10 of 10
BioCentury | Apr 11, 2011
Finance

Playing tax arbitrage

Cephalon Inc. rejected Valeant Pharmaceuticals International Inc. 's hostile bid last week as too low, but the advantages Valeant's tax structure provides make it hard to see how Cephalon can compete for the affections of...
BioCentury | Feb 14, 2011
Finance

Next phase for Phase4

Phase4 Ventures expects to focus more on European investment following its spinout from Nomura. The firm will be raising its first independent fund sometime over the next 12 months. The new firm expects to invest...
BioCentury | Jan 10, 2011
Strategy

A Remembrance: Force of Nature

From the moment you met him, you knew you were dealing with a Force of Nature. A rare combination of determination, imagination and genuine warmth, Frank Baldino was a formidable presence in the life science...
BC Week In Review | Apr 19, 2010
Company News

Cephalon, Mepha deal

Cephalon completed its previously announced acquisition of generics company Mepha for CHF662.4 million ($623.4 million) in cash. Mepha will become a wholly owned subsidiary of Cephalon (see BioCentury, Feb. 8). Cephalon Inc. (NASDAQ:CEPH), Frazer, Pa....
BC Extra | Feb 12, 2010
Financial News

Cephalon beats Street

Cephalon Inc. (NASDAQ:CEPH) report 4Q09 diluted adjusted EPS of $1.66, beating by $0.08 the Street's estimate of $1.58 and up 14% from $1.46 in 4Q08. Fourth quarter revenues were $575.1 million, above the Street's estimate...
BC Week In Review | Feb 8, 2010
Company News

Cephalon, Mepha AG deal

Cephalon announced on Feb. 1 that it will acquire generics company Mepha for CHF622.5 million ($587.9 million) in cash. Cephalon said the deal will expand its generics and branded generics business and double the size...
BioCentury | Feb 8, 2010
Strategy

Footprint for growth

Investors often worry that when companies add low-margin products to a high-margin portfolio, earnings will suffer. Cephalon Inc. Chairman and CEO Frank Baldino says the company's proposed acquisition of generics company Mepha AG should allow...
BioCentury | Feb 8, 2010
Finance

Regulatory milestones

Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) gained $2.88 (10%) to $31.04 last week after FDA approved a BLA for Xiaflex collagenase clostridium histolyticum to treat Dupuytren's contracture, a condition that affects the joints in the hand. Auxilium...
BC Extra | Feb 2, 2010
Top Story

Cephalon to acquire Mepha

Cephalon Inc. (NASDAQ:CEPH) will acquire generics company Mepha AG (Basel, Switzerland) for CHF622.5 million ($587.9 million) in cash. Cephalon said the deal will expand its range of products and double the size of its international...
BC Week In Review | Sep 25, 2000
Company News

Cephalon sales and marketing update

CEPH launched in Switzerland its Modasomil modafinil oral alpha adrenergic stimulant to treat narcolepsy. CEPH licensed Swiss rights to the compound from Mepha Pharma AG (Basel, Switzerland). CEPH markets modafinil under the name Provigil in...
Items per page:
1 - 10 of 10